Skip to content
    Clinical Trials

    Tirzepatide Linked With Greater Lean Body Mass Loss Than Semaglutide in Routine Care

    Murugadoss et alnpj Exercise Medicine and Health

    Tirzepatide Linked With Greater Lean Body Mass Loss Than Semaglutide in Routine Care
    In an observational cohort study evaluating 670,422 first-time users of semaglutide or tirzepatide via an EHR-linked, LLM-enabled body-composition phenotyping pipeline, 7,965 patients had paired pre- and post-treatment measurements over a 12-month period.
    Unadjusted analyses revealed that tirzepatide was associated with a greater relative decline in lean body mass (LBM) compared to semaglutide at 12 months, with a difference of −2.1 percentage points (95% CI −3.8 to −0.3). However, this between-drug disparity was abolished following adjustment for concurrent total weight loss (−0.1 percentage points, 95% CI −1.6 to 1.4). Across both incretin therapies, LBM loss accounted for approximately 20% of total weight lost, indicating that lean tissue reduction scales directly with overall weight loss depth.
    Subgroup phenotyping showed that the exploratory Depletive GLP-1 phenotype—defined as greater than 20% total body weight loss accompanied by greater than 5% LBM loss—occurred more often in tirzepatide-treated individuals than in semaglutide-treated individuals (10.3% vs 6.7%, P < 0.001). Conversely, the Prime phenotype, characterized by less than 5% LBM loss alongside greater than 10% total body weight reduction, presented at comparable frequencies between cohorts (11.8% for tirzepatide vs 12.3% for semaglutide, P = 0.66).
    Functionally, patients experiencing greater LBM loss had an increased frequency of documented reduced exercise tolerance, noted at rates 7.2 and 11.1 percentage points higher in semaglutide- and tirzepatide-treated groups, respectively. The authors concluded that because LBM loss scaled with weight reduction and showed broad inter-individual variability, these findings support prospective assessment of body-composition metrics during incretin therapy.

    Key Takeaways

    • Tirzepatide was associated with greater relative lean body mass loss than semaglutide at 12 months (difference: −2.1 percentage points; 95% CI, −3.8 to −0.3), but this difference attenuated after adjustment for concurrent weight change (−0.1 percentage points; 95% CI, −1.6 to 1.4), with lean mass accounting for approximately 20% of lost weight with either agent.
    • The exploratory depletive phenotype (>20% total weight loss with >5% lean body mass loss) occurred more frequently in patients receiving tirzepatide compared with semaglutide (10.3% vs 6.7%, P < 0.001), whereas the prime phenotype (<5% lean mass loss with >10% total weight loss) occurred at similar rates (11.8% vs 12.3%, P = 0.66).
    • Greater lean body mass loss was clinically relevant, with reduced exercise tolerance documented 7.2 and 11.1 percentage points more frequently in semaglutide- and tirzepatide-treated cohorts, respectively.
    Read the original sourcenpj Exercise Medicine and Health